Medpace Holdings, Inc. (MEDP) Revenue by Segment
Medpace revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Medpace's largest product or service was Metabolic, with $219.07 million or 31% of revenue, up 48.1% from a year earlier. Next: Oncology (30%), Other (14%) and Central Nervous System (12%).
The fastest-growing product or service from a year earlier was Metabolic (+48.1%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Medpace Holdings, Inc.
MEDP
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
Medpace revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Metabolic | $219.1M | $237.6M | $199.3M | $147.9M | 31% |
| Oncology | $209.4M | $201.2M | $192.6M | $188.6M | 30% |
| Other | $98.3M | $93.3M | $106.4M | $118.1M | 14% |
| Central Nervous System | $82.9M | $80.2M | $65.6M | $61.1M | 12% |
| Cardiology | $60.0M | $56.3M | $59.5M | $58.6M | 8% |
| Antiviral and Anti Infective | $37.8M | $38.0M | $36.5M | $29.1M | 5% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Medpace?
Metabolic: $219.07 million, or 31% of revenue, in Q2 fiscal 2026.
What are Medpace's main products and services?
By revenue in Q2 fiscal 2026: Metabolic (31%), Oncology (30%), Other (14%) and Central Nervous System (12%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
